Thu. Feb 6th, 2025

Update: Merck’s Patritumab Deruxtecan Outperforms Doublet Chemotherapy

ByLisa Luckas

09/17/2024
a glass bowl filled with cigarettes sitting on top of a wooden tablePhoto by Markus Spiske
  • Merck’s Patritumab Deruxtecan shows significant improvement in progression-free survival over doublet chemotherapy for advanced EGFR-mutated non-small cell lung cancer in Phase 3 HERTHENA-Lung02 trial.

Tue Sep 17 09:02:07 -2024 UTC– Merck & Co. announced that Patritumab Deruxtecan showed significant progress in patients with advanced EGFR-mutated lung cancer in a Phase 3 trial.

Merck & Co. announced that its new drug, Patritumab Deruxtecan, has shown significant improvement in treating patients with advanced lung cancer. This was observed in a large Phase 3 clinical trial focused on patients with a specific type of lung cancer that has a mutation in the EGFR gene. The drug outperformed the current standard chemotherapy in helping patients live longer without their disease worsening.

Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:

About Lisa

Subscribe to Lisa’s Newsletter today!

Keep Up: Nobot.News Launches Breaking Newsletter

Read more Business News as it happens!

Business

Similar news.
Another Merck study, recently released.
Results from ESMO 2024 in Barcelona.

ByLisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *